Alterity Therapeutics Limited (NASDAQ:ATHE) Short Interest Update

Alterity Therapeutics Limited (NASDAQ:ATHE) was the recipient of a significant increase in short interest during the month of January. As of January 31st, there was short interest totalling 553,500 shares, an increase of 556.6% from the January 15th total of 84,300 shares. Currently, 6.4% of the shares of the stock are short sold. Based on an average daily trading volume, of 448,900 shares, the short-interest ratio is presently 1.2 days.

Alterity Therapeutics Trading Down 2.9 %

NASDAQ ATHE traded down $0.13 during trading hours on Wednesday, hitting $4.22. 40,285 shares of the company were exchanged, compared to its average volume of 1,083,895. Alterity Therapeutics has a 52 week low of $1.00 and a 52 week high of $5.87. The stock has a 50-day moving average price of $3.23 and a 200 day moving average price of $1.97.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the company. Maxim Group lifted their target price on Alterity Therapeutics from $8.00 to $12.00 and gave the stock a “buy” rating in a report on Thursday, January 30th. Benchmark cut Alterity Therapeutics from a “speculative buy” rating to a “hold” rating in a report on Monday, February 3rd.

Institutional Trading of Alterity Therapeutics

A hedge fund recently raised its stake in Alterity Therapeutics stock. HB Wealth Management LLC boosted its position in shares of Alterity Therapeutics Limited (NASDAQ:ATHE) by 34.1% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 31,883 shares of the company’s stock after buying an additional 8,100 shares during the quarter. HB Wealth Management LLC owned approximately 0.44% of Alterity Therapeutics worth $110,000 at the end of the most recent reporting period. 2.14% of the stock is owned by institutional investors.

About Alterity Therapeutics

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia. The company’s lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson’s disease.